Home-Shanghai Leadingtac Pharmaceutical Co., Ltd.

Pioneering
New Modality

Transforming
Novel Medication

Pioneering New Modality，
Transforming Novel Medication

Discovery and development of First-in-class/Best-in-class small molecule innovative drug

Novel discovery platforms of targeted protein degradation (TPD), with a commitment on areas of autoimmunity and oncology, leveraging new unmet medical needs and the synergistic combinations to transform patients life.

More

The company's first pipeline is currently in Phase 1c clinical trials.

More

Leadingtac is dedicated to the discovery and development of nano-SPUD® innovative drug to advance the precision protein degrader system

More

Leadingtac management team has most members from both Chinese, American and European biotech and pharmaceutical companies. Excelling their perspectives and expertise in the field of small molecule drug development, specifically the in the field of protein degradation

More

Science and Technology

We will always share with you a little bit of what we do

A First in China! Leadingtac's Oral KRAS G12D PROTAC Receives Approval from China's CDE to Enter Clinical Trials

The World First! Leadingtac’s Oral KRAS G12D PROTAC Receives U.S. FDA Approval to Enter Clinical Trials

Leadingtac Completes Series B Financing of Over RMB 200 Million to Accelerate Global Development of Targeted Protein Degradation Pipelines ——The funding will propel the clinical development of core assets, including the IRAK4 degrader LT-002-158, and expand the company’s proprietary TPD platform.

First HS patient dosed! Leadingtac IRAK4 Degrader Expands New Indications

Leadingtac Announces First Patient Dosed in Phase Ic Clincial Trial of LT-002, its First Pipeline IRAK4 Degrader in Atopic Dermatitis Patient

Last HV Out！Leadingtac Announces Completion of All Healthy Volunteers Dosed in Phase I Clinical Trial of First Pipeline IRAK4 Degrader

Great news in the New Year! Leadingtac won the “2024 Jin Kai High-Quality Entrepreneurship Award” in Keqiao Economic Development Zone!

Leadingtac Secures Over $14 million Series A Financing secures for IRAK4 degraders

Leadingtac Announces First Healthy Volunteer Dosed in a Phase 1 Clinical Program of LT-002, a Potentially best-in-class IRAK4 degrader

LeadingTac: Leading the Targeted Protein Degradation Track to Make Global Innovative Innovative Drugs

A First in China! Leadingtac's Oral KRAS G12D PROTAC Receives Approval from China's CDE to Enter Clinical Trials

The World First! Leadingtac’s Oral KRAS G12D PROTAC Receives U.S. FDA Approval to Enter Clinical Trials

Leadingtac Completes Series B Financing of Over RMB 200 Million to Accelerate Global Development of Targeted Protein Degradation Pipelines ——The funding will propel the clinical development of core assets, including the IRAK4 degrader LT-002-158, and expand the company’s proprietary TPD platform.

First HS patient dosed! Leadingtac IRAK4 Degrader Expands New Indications

Leadingtac Announces First Patient Dosed in Phase Ic Clincial Trial of LT-002, its First Pipeline IRAK4 Degrader in Atopic Dermatitis Patient

Last HV Out！Leadingtac Announces Completion of All Healthy Volunteers Dosed in Phase I Clinical Trial of First Pipeline IRAK4 Degrader

Great news in the New Year! Leadingtac won the “2024 Jin Kai High-Quality Entrepreneurship Award” in Keqiao Economic Development Zone!

Leadingtac Secures Over $14 million Series A Financing secures for IRAK4 degraders

Leadingtac Announces First Healthy Volunteer Dosed in a Phase 1 Clinical Program of LT-002, a Potentially best-in-class IRAK4 degrader

LeadingTac: Leading the Targeted Protein Degradation Track to Make Global Innovative Innovative Drugs

Blaze a new path in the development of targeted protein degradation drugs.

Since 2019

Major Milestones

Management Team

Industry Information

Employment Philosophy

Development Space

Suite 1102-1104, Building 2, No. 4560 Jinke Road, Pudong New Area, Shanghai,China

Suite 1001, Building 9, Dongsheng Huigu Industrial Park, 1299 Kehai Avenue, Anchang Street, Keqiao District, Shaoxing, Zhejiang Province,China

hr@leadingtac.com/yxie@leadingtac.com

Company Mailbox

hr@leadingtac.com
yxie@leadingtac.com

Official Account

Copyright © 2026 Shanghai Leadingtac Pharmaceutical Co., Ltd. All Rights Reserved. 沪ICP备2022020812号-1

Design by jijin